Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2014 · 10-Q
Revenue$56.00K$56.00K+14.3% vs Q2 2013 Net Income-$1.08M-$1.08MN/M vs Q2 2013 EPS Diluted-$0.17-$0.17N/M vs Q2 2013 Operating Income-$3,241,598N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,668,625N/M Margins · derivedOperating margin-5788.6%−943.4 pt vs Q2 2013
Net margin-1923.4%+8831.9 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 7, 2014 · 38 d after period end